DGX
VENTE TOTALE: 10 000 titres (~2 427 200,00 $ US)
- Insiders
- Davis J. E.
- Total bought
- —
- Total sold
- $2,427,200
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-07
DGX presents a weak overall profile: a low catalyst score of 20 with no identifiable event-driven trigger, combined with constrained fundamentals (liquidity 55, fundamentals trend 45) and a notable insider sell of $2.4M…
The first sentence of the analysis written for DGX on 2026-09-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 31.9% | 32.9% | 33.2% | 34.7% | 39.0% | |
| Ebit Margin | 14.7% | 14.2% | 14.0% | 14.0% | 25.5% | |
| Ebitda Margin | 19.9% | 19.2% | 18.7% | 18.4% | 29.3% | |
| Operating Profit Margin | 14.5% | 13.6% | 13.6% | 14.4% | 22.1% | |
| Pretax Profit Margin | 12.3% | 12.1% | 12.5% | 12.9% | 24.8% | |
| Continuous Operations Profit Margin | 9.5% | 9.3% | 9.8% | 10.3% | 19.3% | |
| Net Profit Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | |
| Bottom Line Profit Margin | 9.0% | 8.8% | 9.2% | 9.5% | 18.4% | |
| Current Ratio | 1.044 | 1.103 | 1.307 | 1.224 | 1.564 | |
| Quick Ratio | 0.961 | 1.016 | 1.202 | 1.100 | 1.445 | |
| Solvency Ratio | 0.175 | 0.147 | 0.170 | 0.202 | 0.341 | |
| Cash Ratio | 0.184 | 0.253 | 0.378 | 0.203 | 0.497 | |
| Price To Earnings Ratio | 19.564 | 19.341 | 18.166 | 19.266 | 10.881 | |
| Price To Earnings Growth Ratio | 1.426 | 6.990 | -2.783 | -0.394 | 0.223 | |
| Forward Price To Earnings Growth Ratio | 1.426 | 6.990 | -2.783 | -0.394 | 0.223 | |
| Price To Earnings Diluted Ratio | 19.832 | 19.618 | 18.335 | 19.604 | 11.140 | |
| Price To Earnings Diluted Growth Ratio | 1.439 | 8.678 | -3.181 | -0.403 | 0.234 | |
| Price To Book Ratio | 2.686 | 2.471 | 2.448 | 3.079 | 3.356 | |
| Price To Sales Ratio | 1.746 | 1.696 | 1.669 | 1.836 | 2.005 | |
| Price To Free Cash Flow Ratio | 14.174 | 18.422 | 17.873 | 13.811 | 11.818 | |
| Price To Operating Cash Flow Ratio | 10.213 | 12.553 | 12.140 | 10.563 | 9.685 | |
| Debt To Assets Ratio | 0.426 | 0.439 | 0.392 | 0.367 | 0.351 | |
| Debt To Equity Ratio | 0.965 | 1.046 | 0.872 | 0.800 | 0.741 | |
| Debt To Capital Ratio | 0.491 | 0.511 | 0.466 | 0.444 | 0.426 | |
| Long Term Debt To Capital Ratio | 0.443 | 0.452 | 0.411 | 0.403 | 0.384 | |
| Financial Leverage Ratio | 2.263 | 2.383 | 2.223 | 2.178 | 2.112 | |
| Working Capital Turnover Ratio | 68.328 | 25.313 | 20.469 | 14.806 | 9.505 | |
| Operating Cash Flow Ratio | 0.828 | 0.615 | 0.701 | 1.108 | 1.274 | |
| Operating Cash Flow Sales Ratio | 0.171 | 0.135 | 0.137 | 0.174 | 0.207 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.721 | 0.681 | 0.679 | 0.765 | 0.820 | |
| Debt Service Coverage Ratio | 1.969 | 1.394 | 1.984 | 3.939 | 6.086 | |
| Interest Coverage Ratio | 5.787 | 5.956 | 7.742 | 9.649 | 15.664 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.782 | 1.424 | 2.174 | 6.955 | 8.301 | |
| Operating Cash Flow Coverage Ratio | 0.273 | 0.188 | 0.231 | 0.364 | 0.468 | |
| Capital Expenditure Coverage Ratio | 3.579 | 3.139 | 3.118 | 4.252 | 5.541 | |
| Dividend Paid And Capex Coverage Ratio | 2.143 | 1.765 | 1.762 | 2.423 | 3.136 | |
| Dividend Payout Ratio | 0.356 | 0.380 | 0.368 | 0.322 | 0.155 | |
| Enterprise Value Multiple | 11.741 | 12.293 | 11.694 | 12.388 | 8.081 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 31.9% | ▼-0.9% | ▼-2.4% |
| Ebit Margin | 14.7% | ▲0.5% | ▼-1.8% |
| Ebitda Margin | 19.9% | ▲0.7% | ▼-1.2% |
| Operating Profit Margin | 14.5% | ▲0.9% | ▼-1.1% |
| Pretax Profit Margin | 12.3% | ▲0.2% | ▼-2.6% |
| Continuous Operations Profit Margin | 9.5% | ▲0.1% | ▼-2.2% |
| Net Profit Margin | 9.0% | ▲0.2% | ▼-2.0% |
| Bottom Line Profit Margin | 9.0% | ▲0.2% | ▼-2.0% |
| Current Ratio | 1.044 | ▼-0.059 | ▼-0.204 |
| Quick Ratio | 0.961 | ▼-0.055 | ▼-0.184 |
| Solvency Ratio | 0.175 | ▲0.027 | ▼-0.032 |
| Cash Ratio | 0.184 | ▼-0.069 | ▼-0.119 |
| Price To Earnings Ratio | 19.564 | ▲0.223 | ▲2.120 |
| Price To Earnings Growth Ratio | 1.426 | ▼-5.564 | ▲0.334 |
| Forward Price To Earnings Growth Ratio | 1.426 | ▼-5.564 | ▲0.334 |
| Price To Earnings Diluted Ratio | 19.832 | ▲0.214 | ▲2.126 |
| Price To Earnings Diluted Growth Ratio | 1.439 | ▼-7.239 | ▲0.085 |
| Price To Book Ratio | 2.686 | ▲0.216 | ▼-0.122 |
| Price To Sales Ratio | 1.746 | ▲0.049 | ▼-0.045 |
| Price To Free Cash Flow Ratio | 14.174 | ▼-4.248 | ▼-1.046 |
| Price To Operating Cash Flow Ratio | 10.213 | ▼-2.340 | ▼-0.818 |
| Debt To Assets Ratio | 0.426 | ▼-0.012 | ▲0.031 |
| Debt To Equity Ratio | 0.965 | ▼-0.081 | ▲0.080 |
| Debt To Capital Ratio | 0.491 | ▼-0.020 | ▲0.024 |
| Long Term Debt To Capital Ratio | 0.443 | ▼-0.009 | ▲0.024 |
| Financial Leverage Ratio | 2.263 | ▼-0.120 | ▲0.031 |
| Working Capital Turnover Ratio | 68.328 | ▲43.015 | ▲40.644 |
| Operating Cash Flow Ratio | 0.828 | ▲0.213 | ▼-0.077 |
| Operating Cash Flow Sales Ratio | 0.171 | ▲0.036 | ▲0.006 |
| Free Cash Flow Operating Cash Flow Ratio | 0.721 | ▲0.039 | ▼-0.013 |
| Debt Service Coverage Ratio | 1.969 | ▲0.575 | ▼-1.106 |
| Interest Coverage Ratio | 5.787 | ▼-0.169 | ▼-3.173 |
| Short Term Operating Cash Flow Coverage Ratio | 2.782 | ▲1.358 | ▼-1.546 |
| Operating Cash Flow Coverage Ratio | 0.273 | ▲0.084 | ▼-0.032 |
| Capital Expenditure Coverage Ratio | 3.579 | ▲0.440 | ▼-0.347 |
| Dividend Paid And Capex Coverage Ratio | 2.143 | ▲0.379 | ▼-0.103 |
| Dividend Payout Ratio | 0.356 | ▼-0.024 | ▲0.040 |
| Enterprise Value Multiple | 11.742 | ▼-0.552 | ▲0.502 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $19.26B | $16.75B | $15.44B | $18.15B | $21.63B | |
| Enterprise value | $25.76B | $23.28B | $20.25B | $22.55B | $25.53B | |
| EV / Sales | 2.33x | 2.36x | 2.19x | 2.28x | 2.37x | |
| EV / Op. cash flow | 13.66x | 17.45x | 15.92x | 13.12x | 11.43x | |
| EV / Free cash flow | 18.96x | 25.61x | 23.44x | 17.16x | 13.95x | |
| EV / EBITDA | 11.74x | 12.29x | 11.69x | 12.39x | 8.08x | |
| Net debt / EBITDA | 2.96x | 3.45x | 2.78x | 2.42x | 1.24x | |
| Current ratio | 1.04x | 1.10x | 1.31x | 1.22x | 1.56x | |
| Income quality | 1.80x | 1.45x | 1.40x | 1.69x | 1.07x | |
| Graham number | $114 | $104 | $98 | $97 | $136 | |
| Graham net-net | -$66 | -$69 | -$53 | -$48 | -$40 | |
| Tax burden | 72.9% | 72.9% | 73.9% | 74.0% | 74.5% | |
| Interest burden | 83.7% | 85.2% | 89.4% | 92.5% | 97.3% | |
| Working capital | $100.0M | $223.0M | $557.0M | $347.0M | $988.0M | |
| Invested capital | $13.54B | $13.61B | $11.87B | $11.01B | $11.55B | |
| Return on assets | 6.1% | 5.4% | 6.1% | 7.4% | 14.7% | |
| Operating ROA | 9.9% | 8.9% | 9.4% | 10.8% | 17.2% | |
| Return on tangible assets | 17.6% | 15.7% | 16.7% | 20.9% | 37.3% | |
| Return on equity | 13.8% | 12.9% | 13.5% | 16.1% | 31.0% | |
| Return on invested capital | 8.4% | 7.0% | 7.7% | 9.8% | 15.3% | |
| Return on capital employed | 11.5% | 9.6% | 10.3% | 12.7% | 20.1% | |
| Earnings yield | 5.2% | 5.2% | 5.5% | 5.2% | 9.2% | |
| Free cash flow yield | 7.1% | 5.4% | 5.6% | 7.2% | 8.5% | |
| Capex / Op. cash flow | 27.9% | 31.9% | 32.1% | 23.5% | 18.0% | |
| Capex / Depreciation | 92.5% | 86.2% | 92.9% | 92.4% | 98.8% | |
| Capex / Sales | 4.8% | 4.3% | 4.4% | 4.1% | 3.7% | |
| SG&A / Sales | 17.8% | 17.9% | 17.5% | 19.0% | 16.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.8% | 0.9% | 0.8% | 0.8% | 0.7% | |
| Intangibles / Total assets | 65.2% | 65.7% | 63.5% | 64.8% | 60.7% | |
| Days sales outstanding | 47d | 48d | 48d | 44d | 49d | |
| Days payables outstanding | 78d | 16d | 22d | 18d | 20d | |
| Operating cycle | 56d | 59d | 59d | 55d | 60d | |
| Cash conversion cycle | -22d | 43d | 37d | 37d | 40d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+15.0%EV / Sales ▼-1.0%EV / EBITDA ▼-4.5%EV / Op. cash flow ▼-3.795Earnings yield ▼-0.001Graham number ▲+10.137
Profitability
Return on equity ▲+0.010Return on assets ▲+0.007Return on invested capital ▲+0.015Return on capital employed ▲+0.019Operating ROA ▲+0.010Income quality ▲+0.355Tax burden -0.000
Efficiency
Days sales outstanding ▼-1.641Days payables outstanding ▲+61.937Operating cycle ▼-2.811Cash conversion cycle ▼-64.748Capex / Sales ▲+0.005R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.059Net debt / EBITDA ▼-0.490Working capital ▼-123000000.000Invested capital ▼-65000000.000Intangibles / Total assets ▼-0.005
Change over 5 years
Valuation
Market cap ▼-10.9%EV / Sales ▼-1.3%EV / EBITDA ▲+45.3%EV / Op. cash flow ▲+2.227Earnings yield ▼-0.041Graham number ▼-22.092
Profitability
Return on equity ▼-0.171Return on assets ▼-0.085Return on invested capital ▼-0.068Return on capital employed ▼-0.086Operating ROA ▼-0.073Income quality ▲+0.730Tax burden ▼-0.016
Efficiency
Days sales outstanding ▼-2.081Days payables outstanding ▲+57.936Operating cycle ▼-4.438Cash conversion cycle ▼-62.374Capex / Sales ▲+0.010R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.520Net debt / EBITDA ▲+1.727Working capital ▼-888000000.000Invested capital ▲+1987000000.000Intangibles / Total assets ▲+0.045
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-11-03 | Julie Johnson | Sale | $1,001 - $15,000 |
| 2025-10-30 | Julie Johnson | Purchase | $1,001 - $15,000 |
| 2025-10-30 | Julie Johnson | Sale | $1,001 - $15,000 |
| 2025-07-24 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2025-04-28 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2025-03-10 | Carol Devine Miller | Sale | $15,001 - $50,000 |
| 2025-03-10 | Carol Devine Miller | Sale (Full) | $1,001 - $15,000 |
| 2025-01-24 | Gilbert Ray Cisneros | Sale | $1,001 - $15,000 |
| 2024-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-04-04 | Earl Blumenauer | Sale (Full) | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-14 | Carol Devine Miller | Purchase | $1,001 - $15,000 |
| 2022-08-03 | Kathy E. Manning | Sale (Full) | $1,001 - $15,000 |
| 2022-07-20 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2022-03-31 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2022-03-31 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2022-03-14 | Earl Blumenauer | Sale (Full) | $1,001 - $15,000 |
| 2022-02-24 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-28 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-01-28 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-07 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2022-01-07 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2021-12-14 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2021-07-28 | Carol Devine Miller | Purchase | $15,001 - $50,000 |
| 2021-04-09 | Sara Jacobs | Sale (Full) | $50,001 - $100,000 |
| 2020-06-01 | Dean Phillips | Sale (Partial) | $1,001 - $15,000 |
| 2020-04-02 | Dean Phillips | Sale (Partial) | $1,001 - $15,000 |
| 2020-03-02 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2020-02-10 | Dean Phillips | Sale (Partial) | $1,001 - $15,000 |
| 2020-01-17 | Dean Phillips | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-01 Connor Clark & Lunn Investment Management Ltd. Buys Shares of 3,113 Quest Diagnostics Incorporated $DGX Connor Clark and Lunn Investment Management Ltd. purchased a new position in Quest Diagnostics Incorporated (NYSE: DGX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,113 shares of the medical research company''s stock, valued at approximately $660,000. Other
- 2026-08-31 Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy? The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here''s why you should take advantage.
- 2026-08-28 Bank OZK Makes New Investment in Quest Diagnostics Incorporated $DGX Bank OZK purchased a new position in Quest Diagnostics Incorporated (NYSE: DGX) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 15,322 shares of the medical research company''s stock, valued at approximately $3,247,000. Other institutional investors and hedge funds have also made changes to their
- 2026-08-27 Artia Global Partners LP Acquires New Holdings in Quest Diagnostics Incorporated $DGX Artia Global Partners LP purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE: DGX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 65,122 shares of the medical research company''s stock, valued at approximately $13,803,000. Quest Diagnostics
- 2026-08-25 Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference SECAUCUS, N.J., Aug. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company''s strategy, performance and the latest market developments and trends during the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026, at 10:50 a.m.
- 2026-08-25 Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com Individuals in the U.S. can now add Humanity Biological Age''s lab-informed insights to select health profile tests purchased through Quest''s consumer-initiated testing platform LONDON, Aug. 25, 2026 /PRNewswire/ -- Humanity Health Inc. ("Humanity"), the longevity science company, and Quest Diagnostics (NYSE: DGX) today announced that Humanity Biological Age, Humanity''s scientifically validated model for measuring biological age from biomarker lab test results, is now available in the United States for the first time through questhealth.com, Quest''s consumer-initiated testing platform. Individuals now have the option to select the Humanity Biological Age add-on when purchasing select health profile tests from questhealth.com including Elite Health Profile, Men''s and Women''s Comprehensive Health Profiles, and Fitness Profile — Elite, with no additional blood draw needed.
- 2026-08-25 Quest Diagnostics (NYSE:DGX) Sets New 12-Month High – Here’s What Happened Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report)''s share price reached a new 52-week high during trading on Tuesday. The stock traded as high as $246.00 and last traded at $243.9570, with a volume of 837684 shares changing hands. The stock had previously closed at $244.39. Analyst Upgrades and Downgrades A number of brokerages
- 2026-08-24 Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company''s strategy, performance and the latest market developments and trends during the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on Monday, September 14, 2026, at 10:00 a.m.
- 2026-08-24 Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer''s Disease Pathology Test to join the company''s expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10% indeterminate rate, so more patients can receive an actionable insight SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced two new developments for its Quest AD-Detect® portfolio of blood-based biomarker tests for Alzheimer''s disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer''s disease.
- 2026-08-21 Is it the Right Time to Retain DGX Stock in Your Portfolio? Quest Diagnostics'' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.